Analytical Data
-
基因名
HIN-1/SCGB3A1
- Application
-
别名
HIN1; HIN-1; LU105; PnSP-2; UGRP2; Cytokine High In Normal-1; Pneumo Secretory Protein 2; High in normal 1; Uteroglobin-related protein 2
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q96QR1
-
表达区间
Phe21~Gly104
-
分子量
38kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HIN-1, a protein originally identified in the context of breast cancer, is a member of the secretoglobin family and serves as a potential biomarker for various cancer types. Research has indicated that HIN-1 expression may be suppressed during tumorigenesis, particularly in the breast and other epithelial cancers, making it a candidate for both diagnostic and therapeutic applications. The SCGB3A1 gene, closely related to HIN-1, encodes a secreted protein that is also implicated in tumor biology. Studies have shown that recombinant HIN-1/SCGB3A1 proteins can elicit immune responses, suggesting their potential as vaccine candidates or targets for immune modulation in cancer therapy. Understanding the structural and functional properties of these recombinant proteins is crucial for elucidating their roles in tumor biology and for developing novel therapeutic strategies. By investigating the interactions between HIN-1/SCGB3A1 and the immune system, researchers aim to enhance our knowledge of cancer progression and identify new avenues for treatment, ultimately improving patient outcomes in oncology.
